表观遗传修饰的进展 调节在低毒环境中的药物载体
Ziqin Wei1,2, Hongfang Mu1, Xiaojing Zhang1
1PLA Key Laboratory of the Plateau of the Environmental Damage Control, the 940th Hospital of Logistics Support Force of PLA, Lanzhou, 730050, China.
Current drug delivery
|June 28, 2024
概括
缺氧通过表观遗传修饰显著改变药物载体,影响药物的药理动力学. 了解这些变化对于安全的高空药物治疗至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 环境医学 环境医学
背景情况:
- 药物运输器对药物的药理动力学有重大影响,特别是在低氧条件下.
- 缺氧通过各种调节途径改变药物载体表达,包括HIF-1,核受体和炎症因素.
- 表观遗传修饰是低氧调节药物载体的关键机制,影响ADME过程.
研究的目的:
- 综合审查缺氧对药物载体和表观遗传修饰的影响.
- 在低氧条件下探索药物载体表达上表观遗传修饰的调节机制.
- 为了解高海拔处药物载体的表观遗传调节提供参考,并指导安全的药物治疗实践.
主要方法:
- 关于缺氧,药物载体和表观遗传修饰的研究的文献综述.
- 分析涉及缺氧诱导因子 (HIF-1),核受体和炎症因子的调节途径.
- 对影响转运体表达的表观遗传机制 (例如,DNA甲基化,基因素修饰) 的当前知识的综合.
主要成果:
- 缺氧诱导药物载体水平和功能的显著变化.
- 人们越来越认识到表观遗传修饰是低氧环境中药物载体的关键调节者.
- 高海拔低氧对药物药理动力学提出了独特的挑战,原因是转运体表达的改变.
结论:
- 表观遗传修饰在调节低氧对药物载体的影响方面发挥着至关重要的作用.
- 对这些表观遗传机制的进一步研究对于优化低氧条件下的药物治疗至关重要,特别是在高海拔地区.
- 了解这些相互作用将有助于为高海拔人口开发更安全,更有效的药物治疗策略.
相关概念视频
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Carrier-Mediated Transport
335
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
335
Nonlinear Pharmacokinetics: Role of Transporters
47
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
47
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Hepatic Drug Clearance: Role of Transporters
54
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
54
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38


